KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis
USA - NASDAQ:KRYS - US5011471027 - Common Stock
199.88 USD
-3.38 (-1.66%)
199.88 USD
0 (0%)
KRYS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. KRYS has an excellent financial health rating, but there are some minor concerns on its profitability. KRYS may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make KRYS suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year KRYS was profitable.
In the past year KRYS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
In the past 5 years KRYS reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of KRYS (12.89%) is better than 94.94% of its industry peers.
Looking at the Return On Equity, with a value of 14.10%, KRYS belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 12.87%, KRYS belongs to the top of the industry, outperforming 95.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.89% | ||
| ROE | 14.1% | ||
| ROIC | 12.87% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of KRYS (40.85%) is better than 98.31% of its industry peers.
Looking at the Operating Margin, with a value of 42.26%, KRYS belongs to the top of the industry, outperforming 98.88% of the companies in the same industry.
The Gross Margin of KRYS (93.37%) is better than 92.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.26% | ||
| PM (TTM) | 40.85% | ||
| GM | 93.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KRYS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for KRYS has been increased compared to 1 year ago.
Compared to 5 years ago, KRYS has more shares outstanding
KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
KRYS has an Altman-Z score of 37.53. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of KRYS (37.53) is better than 95.32% of its industry peers.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 37.53 |
ROIC/WACC1.47
WACC8.74%
2.3 Liquidity
KRYS has a Current Ratio of 9.68. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS has a better Current ratio (9.68) than 80.52% of its industry peers.
KRYS has a Quick Ratio of 9.33. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS's Quick ratio of 9.33 is fine compared to the rest of the industry. KRYS outperforms 79.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.68 | ||
| Quick Ratio | 9.33 |
3. Growth
3.1 Past
KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 276.84%, which is quite impressive.
KRYS shows a strong growth in Revenue. In the last year, the Revenue has grown by 473.02%.
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
Revenue 1Y (TTM)473.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
3.2 Future
The Earnings Per Share is expected to grow by 60.32% on average over the next years. This is a very strong growth
KRYS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.30% yearly.
EPS Next Y70.36%
EPS Next 2Y62.16%
EPS Next 3Y55.07%
EPS Next 5Y60.32%
Revenue Next Year32.01%
Revenue Next 2Y39.8%
Revenue Next 3Y41.2%
Revenue Next 5Y32.3%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 29.97, KRYS can be considered very expensive at the moment.
KRYS's Price/Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 93.82% of the companies in the same industry.
When comparing the Price/Earnings ratio of KRYS to the average of the S&P500 Index (26.13), we can say KRYS is valued inline with the index average.
The Price/Forward Earnings ratio is 25.42, which means the current valuation is very expensive for KRYS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 91.57% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.35. KRYS is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.97 | ||
| Fwd PE | 25.42 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 91.76% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, KRYS is valued cheaply inside the industry as 93.45% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.19 | ||
| EV/EBITDA | 31.05 |
4.3 Compensation for Growth
KRYS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KRYS has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 55.07% in the coming years.
PEG (NY)0.43
PEG (5Y)N/A
EPS Next 2Y62.16%
EPS Next 3Y55.07%
5. Dividend
5.1 Amount
KRYS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
199.88
-3.38 (-1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.05%
Inst Owner Change-0.4%
Ins Owners11.86%
Ins Owner Change-1.19%
Market Cap5.78B
Revenue(TTM)290.51M
Net Income(TTM)146.72M
Analysts84.44
Price Target219.95 (10.04%)
Short Float %11.65%
Short Ratio9.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.87%
Min EPS beat(2)-13.89%
Max EPS beat(2)12.14%
EPS beat(4)2
Avg EPS beat(4)6.3%
Min EPS beat(4)-13.89%
Max EPS beat(4)27.68%
EPS beat(8)3
Avg EPS beat(8)-4.07%
EPS beat(12)5
Avg EPS beat(12)-8.82%
EPS beat(16)7
Avg EPS beat(16)-7.79%
Revenue beat(2)1
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-10.17%
Max Revenue beat(2)2.42%
Revenue beat(4)1
Avg Revenue beat(4)-2.48%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.42%
Revenue beat(8)4
Avg Revenue beat(8)8.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.77%
PT rev (3m)3.67%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)-16.01%
EPS NY rev (1m)0.06%
EPS NY rev (3m)-11.47%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)-8.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.97 | ||
| Fwd PE | 25.42 | ||
| P/S | 16.1 | ||
| P/FCF | 31.19 | ||
| P/OCF | 29.6 | ||
| P/B | 5.56 | ||
| P/tB | 5.56 | ||
| EV/EBITDA | 31.05 |
EPS(TTM)6.67
EY3.34%
EPS(NY)7.86
Fwd EY3.93%
FCF(TTM)6.41
FCFY3.21%
OCF(TTM)6.75
OCFY3.38%
SpS12.41
BVpS35.96
TBVpS35.96
PEG (NY)0.43
PEG (5Y)N/A
Graham Number73.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.89% | ||
| ROE | 14.1% | ||
| ROCE | 14.44% | ||
| ROIC | 12.87% | ||
| ROICexc | 36.62% | ||
| ROICexgc | 36.62% | ||
| OM | 42.26% | ||
| PM (TTM) | 40.85% | ||
| GM | 93.37% | ||
| FCFM | 51.63% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 195.35% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 124.54% | ||
| Profit Quality | 126.39% | ||
| Current Ratio | 9.68 | ||
| Quick Ratio | 9.33 | ||
| Altman-Z | 37.53 |
F-Score8
WACC8.74%
ROIC/WACC1.47
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
EPS Next Y70.36%
EPS Next 2Y62.16%
EPS Next 3Y55.07%
EPS Next 5Y60.32%
Revenue 1Y (TTM)473.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
Revenue Next Year32.01%
Revenue Next 2Y39.8%
Revenue Next 3Y41.2%
Revenue Next 5Y32.3%
EBIT growth 1Y3666.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.9%
EBIT Next 3Y73.68%
EBIT Next 5YN/A
FCF growth 1Y242.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y290.87%
OCF growth 3YN/A
OCF growth 5YN/A
KRYSTAL BIOTECH INC / KRYS FAQ
Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?
ChartMill assigns a fundamental rating of 6 / 10 to KRYS.
What is the valuation status of KRYSTAL BIOTECH INC (KRYS) stock?
ChartMill assigns a valuation rating of 7 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Undervalued.
What is the profitability of KRYS stock?
KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.
What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?
The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 8 / 10.